Harvard Bioscience (HBIO) Non-Current Debt (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Non-Current Debt data on file, last reported at $36.2 million in Q1 2026.

• On a quarterly basis, Non-Current Debt changed N/A year-over-year to $36.2 million in Q1 2026; TTM through Mar 2026 was $36.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $35.9 million, changed N/A from the prior year.
• Non-Current Debt for Q1 2026 stood at $36.2 million, up from $35.9 million in the prior quarter.
• Over the last five years, Non-Current Debt for HBIO reached as high as $49.0 million in Q1 2022 and fell as low as $31.9 million in Q1 2024.
• Historically, Non-Current Debt has averaged $39.9 million across 5 years, with a median of $37.9 million in 2024.
• Across the five-year window, Non-Current Debt gained 17.7% in 2022 and decreased 27.61% in 2024, its largest moves.
• Year by year, Non-Current Debt stood at $43.0 million in 2022, then decreased by 15.0% to $36.6 million in 2023, then increased by 3.54% to $37.9 million in 2024, then decreased by 5.25% to $35.9 million in 2025, then climbed by 0.95% to $36.2 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $36.2 million in Q1 2026, $35.9 million in Q4 2025, and $37.9 million in Q3 2024.